BACKGROUND: Obese men are at higher risk of advanced prostate cancer and cancer-specific mortality; however, the biology underlying this association remains unclear. This study examined gene expression profiles of prostate tissue to identify biological processes differentially expressed by obesity status and lethal prostate cancer. METHODS: Gene expression profiling was performed on tumor (n 5 402) and adjacent normal (n 5 200) prostate tissue from participants in 2 prospective cohorts who had been diagnosed with prostate cancer from 1982 to 2005. Body mass index (BMI) was calculated from the questionnaire immediately preceding cancer diagnosis. Men were followed for metastases or prostate cancer-specific death (lethal disease) through 2011. Gene Ontology biological processes differentially expressed by BMI were identified using gene set enrichment analysis. Pathway scores were computed by averaging the signal intensities of member genes. Odds ratios (ORs) for lethal prostate cancer were estimated with logistic regression. RESULTS: Among 402 men, 48% were healthy weight, 31% were overweight, and 21% were very overweight/obese. Fifteen gene sets were enriched in tumor tissue, but not normal tissue, of very overweight/obese men versus healthy-weight men; 5 of these were related to chromatin modification and remodeling (false-discovery rate < 0.25). Patients with high tumor expression of chromatinrelated genes had worse clinical characteristics (Gleason grade > 7, 41% vs 17%; P 5 2 3 10 -4 ) and an increased risk of lethal disease that was independent of grade and stage (OR, 5.26; 95% confidence interval, 2.37-12.25). CONCLUSIONS: This study improves our understanding of the biology of aggressive prostate cancer and identifies a potential mechanistic link between obesity and prostate cancer death that warrants further study. Cancer 2017;123:4130-8.
INTRODUCTION
The identification of risk factors that drive prostate cancer progression has been a challenge. Obesity is a modifiable risk factor linked to advanced disease and worse cancer-specific outcomes among prostate cancer patients. 1, 2 Because of the high rates of obesity, an understanding of the relationship between excess body weight and worse prostate cancer outcomes has important clinical and public health implications. Although several mechanisms have been proposed, 3, 4 what drives the association between obesity and aggressive prostate cancer remains poorly understood.
In this study, we sought to explore the link between excess body weight and lethal prostate cancer using whole-transcriptome gene expression profiles of prostate tissue. We assessed differences in gene expression in tumor tissue and adjacent normal tissue according to prediagnosis body mass index (BMI) and examined the role of these genes in prostate cancer-specific mortality.
MATERIALS AND METHODS

Study Population
This study was nested among prostate cancer patients in two prospective studies: the Physicians' Health Study (PHS) and the Health Professionals Follow-Up Study (HPFS). PHS I and PHS II began in 1982 and 1997, respectively, as randomized primary prevention trials of aspirin and supplements among 29,067 US physicians. 5, 6 HPFS is an ongoing cohort study of 51,529 US health professionals followed since 1986. 7 Both cohorts completed annual or biennial questionnaires on lifestyle and health. Incident prostate cancer was confirmed by review of medical records and pathology reports. The studies were approved by institutional review boards at the Harvard T. H. Chan School of Public Health and Partners Health Care. Written informed consent was obtained from study participants.
After confirmation of a prostate cancer diagnosis, archival formalin-fixed, paraffin-embedded (FFPE) prostate tissue specimens from radical prostatectomy or transurethral resection of the prostate (TURP) were retrieved from treating hospitals. Gene expression profiling was performed on a subset of the cases with available tissue selected using an extreme case sampling design. In total, 402 patients diagnosed between 1982 and 2005 were included; they comprised 113 lethal cases (metastatic disease or prostate cancer death) and 289 indolent cases (survived 8 years after diagnosis without evidence of metastases). For 200 of these men, we also profiled adjacent normal tissue.
Gene Expression Profiling
To measure gene expression in archival FFPE tissue specimens, whole-transcriptome amplification with the WTOvation FFPE system (version 2; NuGEN) was paired with microarray technologies via GeneChip Human Gene 1.0 ST microarray (Affymetrix), as previously described. 8, 9 We processed expression profiles by regressing out technical variables, including messenger RNA concentration, block age, batch (96-well plate), percentage of probes above the background, log-transformed average background signal, and median of the perfect match probes for each probe intensity of the raw data. The residuals were shifted to the original mean expression values and normalized using the robust multi-array average method. 10, 11 We mapped gene names to Affymetrix transcript cluster identifiers with the NetAffx annotations as implemented in Bioconductor annotation package pd.hugene.1.0.st.v1; this resulted in 20,254 unique gene names. Gene expression data are available through the Gene Expression Omnibus (GSE79021).
Anthropometric Data
BMI was calculated using height and weight reported on the questionnaire immediately preceding cancer diagnosis. In the HPFS, self-reported measurements of weight showed high validity. 12 The mean prediagnosis BMI was 25.4 kg/m 2 (range, 19.0-36.8 kg/m 2 ), and the mean time between the BMI measurement and prostate cancer diagnosis was 1.3 years (range, 0-11.3 years). Because the number of men in our study above the World Health Organization cutoff for obesity (BMI 30 kg/m 2 ) was low (n 5 27), we divided BMI into the following categories for subsequent analyses: 18.5 to <25 (healthy weight), 25 to <27.5 (overweight), and 27.5 kg/m 2 (very overweight/obese). A sensitivity analysis using BMI 30 kg/m 2 for the top category was also performed.
Clinical and Follow-Up Data
Information about age and date of diagnosis, prostatespecific antigen (PSA) at diagnosis, and clinical and pathologic stages was abstracted from medical records and pathology reports. Study pathologists provided a standardized histopathologic review of each case, including Gleason grading. Information on the development of metastatic disease was collected through follow-up questionnaires. Review of medical records and death certificates was used to determine date and cause of death. Lethal prostate cancer was defined as distant metastases or prostate cancer-specific death with follow-up through March 2011 (PHS) or December 2011 (HPFS).
Statistical Analysis
Linear regression, as implemented in the Bioconductor package limma, was used to assess differential expression of individual genes by BMI. 13 Gene set enrichment analysis (GSEA) 14 was performed to test the association between BMI and expression of 589 Gene Ontology ). An enrichment score (ES) was calculated for each gene set using a weighted Kolmogorov-Smirnoff statistic, and the top-ranked genes contributing to the ES were identified as the leading-edge subset. A positive ES indicated gene set enrichment at the top of the ranked list (upregulated gene set); a negative ES indicated gene set enrichment at the bottom of the ranked list (downregulated gene set). Significance was estimated with 10,000 phenotype-based permutations. The normalized ES and the false-discovery rate (FDR) were used to identify the top Gene Ontology biological processes differentially expressed by prediagnosis BMI status. Gene sets with an FDR < 0.25 were considered for subsequent analyses. The Enrichment Map Cytoscape plugin 15 was used to visualize GSEA results as gene set networks.
To further explore the 5 chromatin-related gene sets identified by GSEA, we created a metagene score representing chromatin gene expression by averaging the normalized (mean-centered, variance-scaled) expression values of the leading-edge genes from these gene sets.
We used t tests to compare mean scores between tumor tissue and adjacent normal tissue, and we used Pearson correlations to measure the relationship between the score and BMI. Logistic regression adjusted for age and year at diagnosis was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for the association between the metagene score and lethal prostate cancer. P values were from the Wald test. We adjusted for Gleason grade and clinical stage to test whether the score independently predicted lethal cancer. Finally, we used logistic regression to evaluate whether the metagene score mediated the association between BMI and lethal prostate cancer, with adjustment for age and date at diagnosis, Gleason grade, and clinical stage. Simple mean imputation was used for individuals missing clinical stage (n 5 7). R version 3.1.0 was used for all other analyses. All statistical tests were 2-sided, with P values < .05 considered statistically significant. We compared gene expression in the highest and lowest BMI categories. No individual genes were significantly differentially expressed by BMI in tumor or adjacent normal tissue after adjusting for multiple comparisons (data not shown). To test for sets of functionally related genes with subtle but coordinated changes in expression, we applied GSEA.
RESULTS
14 GSEA identified 15 gene sets upregulated and 2 gene sets downregulated in tumor tissue of very overweight/ obese patients versus healthy-weight patients with an FDR < 0.25 ( Fig. 1 and Supporting Tables 1 and 2 [see online supporting information]). Among these top results, there were several networks of overlapping gene sets involved in chromatin regulation, RNA processing, and cellular disassembly (Fig. 2) . These pathways were not differentially expressed in adjacent normal tissue, and this suggests that the results are tumor-specific (Supporting Tables 3 and 4 [see online supporting information]). To address differences in sample sizes for tumor and adjacent normal tissue, we repeated the GSEA for the subset of tumor samples that also had normal tissue data and found that 9 of 15 upregulated gene sets from the full analysis remained enriched at an FDR < 0.25 (Supporting Tables 5 and 6 [see online supporting  information] ). Finally, we ran a sensitivity analysis excluding 34 cases with gene expression assayed in TURP specimens. Although the overall significance level decreased slightly because of a decrease in sample size, the top pathways remained largely unchanged (Supporting Tables 7-12 [see online supporting information]).
Characterization of the Chromatin Gene Set Network
Five of the 15 gene sets enriched in tumor tissue of very overweight/obese patients included chromatin modification and remodeling genes involved in the regulation of chromatin structure and function (Fig. 2) . All 5 of these chromatin-related gene sets were also ranked in the top 10 in a sensitivity analysis using 30 kg/m 2 as the cutoff for the high-BMI group (data not shown). Given the extensive interplay between epigenetics and metabolism and the critical role that this interplay has in cancer, we chose to explore Original Article these findings further. 16 Similar analyses were performed for the other gene sets identified but will not be the focus of this article. These results can be found in the online supporting information (Supporting Tables 13-15) .
To characterize the chromatin gene set network (Fig. 2) , we created a metagene score based on expression levels of the 35 genes that composed the GSEA leadingedge subset; they were all upregulated in the high-BMI category (Table 2; see Supporting Table 16 for functional annotations [see online supporting information]). This chromatin gene score was greater in tumor tissue than in adjacent normal tissue (P 5 2 3 10 -4
). As expected, the chromatin gene score was positively associated with prediagnosis BMI in tumor tissue (P 5 6 3 10 -5 ) but not in adjacent normal tissue (P 5 .46). Table 17 [see online supporting information]).
TURP samples (Supporting
BMI, Chromatin Gene Expression, and Lethal Prostate Cancer
To explore whether chromatin modification and remodeling mediates the relationship between excess body weight and lethal prostate cancer, we assessed the association between BMI and lethal cancer with and without adjustment for the tumor chromatin gene score. Per 5-unit increase in prediagnosis BMI, the OR for lethal prostate cancer was 1.70 (95% CI, 1.16-2.53). Adjustment for the chromatin score reduced this OR to 1.41 (95% CI, 0.94-2.12). Additional adjustment for Gleason grade and clinical TNM stage did not affect these results (results not shown).
DISCUSSION
There is compelling evidence linking obesity to aggressive prostate cancer, but the biology underlying this relationship is unclear. We found several networks of gene sets involved in chromatin regulation, RNA processing, and cellular disassembly enriched in tumor tissue of overweight and obese prostate cancer patients in comparison with healthy-weight patients. Focusing on chromatin-related gene sets, we found that tumors with high expression of these genes had higher Gleason grades and that these patients were at increased risk of lethal prostate cancer independently of the grade. This suggests that obesity may promote tumor progression in part by influencing the epigenetic state of prostate cancer.
Epigenetic alterations are a common feature of cancer and are emerging as important drivers of tumor progression. 17 In prostate cancer, DNA methylation has been linked to metastatic disease. 18 In addition, extensive remodeling of the histone code occurs in prostate cancer and, in cooperation with DNA methylation, results in the transcription of key oncogenes, microRNAs, and cancer biomarkers. 19 The current analysis identified genes encoding chromatin remodeling factors and histone modification enzymes, including histone deacetylases. These mechanisms work together to regulate gene transcription as well as other cellular processes, including DNA replication and DNA damage repair. 20 Histone deacetylase overexpression in prostate cancer specimens has been linked to adverse tissue features and worse outcomes. 21 Furthermore, global histone modification patterns have been correlated with recurrence. 22 Epigenetic regulation mediates the reversible effects of environmental exposures and lifestyle factors on carcinogenesis and tumor progression. 23 Observational and experimental studies have begun to provide evidence for epigenetic alterations related to obesity; however, most human studies in this area were conducted in blood or adipose tissue rather than tumor tissue and focused on DNA methylation. 24 Our findings suggest that obesity affects epigenetic regulation in prostate tumor tissue through chromatin-related processes.
Interestingly, our analysis of normal tissue found no association between BMI and chromatin-related gene expression, and this suggests that characteristics specific to tumor tissue may induce susceptibility to the effects of excess body weight. Along these lines, our group previously demonstrated that obesity is linked to worse prognosis among men with tumors harboring the TMPRSS2:ERG gene fusion, 25 and this supports the idea Original Article BMI at treatment and found an association of BMI with altered expression of lipid metabolism and cholesterol homeostasis genes. 26 A second study focused on gene expression in periprostatic adipose tissue by BMI among 18 prostatectomy patients. 27 These authors found altered expression of genes involved in adipogenic/antilipolytic, proliferative/antiapoptotic, and mild immunoinflammatory processes in obese subjects. Most recently, a gene expression study assessing metabolic pathway genes with respect to BMI and prostate cancer outcomes among patients who had undergone prostatectomy identified aberrant metabolic gene expression associated with prostate cancer metastases, but no relation was found with BMI. 28 The strengths of our study include its prospective design, well-characterized data on clinical and pathologic measures (including re-review of Gleason grade), and long-term follow-up, which allowed the study of lethal prostate cancer as the outcome. The cohort is almost exclusively composed of white men, and our conclusions may not apply to men of other ethnic groups. A potential limitation of the study is the use of BMI as an imperfect measure of obesity; however, BMI is the most widely used method for assessing adiposity in epidemiological studies, and its correlation with obesity-related biomarkers is comparable to more direct measures of body fatness. 29 We cannot completely rule out the idea that obesity affects prostate cancer outcomes at least in part through its effect on detection and treatment rather than through true biological differences in the tumors themselves. 30 To address PSA detection bias, Ma et al 31 tested the association between BMI and prostate cancer mortality in the PHS separately by pre-PSA and PSA screening eras and noted that the association remained largely unchanged. Although obese patients may receive different treatments than nonobese patients, 30 our study includes primarily men who underwent prostatectomy as a curative treatment; this limits the possible impacts of treatment differences that are observed in the overall patient population.
This analysis provides a comprehensive look at BMI-associated gene expression alterations in prostate tumor tissue. The findings improve our understanding of the biology of aggressive prostate cancer and provide additional support for a causal relationship between excess body weight and prostate cancer survival. Many new epigenetic targets are emerging for the treatment of cancer. If confirmed, this study could provide insight into novel therapeutic targets that could augment lifestyle changes for men diagnosed with the disease.
